Daniele Starnoni1, Roy Thomas Daniel1, Laura Marino2, Nelly Pitteloud2, Marc Levivier1, Mahmoud Messerer3. 1. Service de Neurochirurgie, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (Unil), Rue du Bugnon 46, 1011, Lausanne, Switzerland. 2. Service d'Endocrinologie, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (Unil), Lausanne, Switzerland. 3. Service de Neurochirurgie, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (Unil), Rue du Bugnon 46, 1011, Lausanne, Switzerland. mahmoud.messerer@chuv.ch.
Abstract
BACKGROUND: In 2010, the Acromegaly Consensus Group revised the criteria for cure of acromegaly and thus rates of surgical remission need to be revised in light of these new thresholds. Two subgroups consisted of patients with discordant GH and IGF-1 levels and patients in remission according to the 2000 criteria, but not to the 2010 criteria, have been reported after adenomectomy and for these subgroups the precise incidence and management has not been established. The objective of the study was to update rates of surgical remission and complications and to evaluate the incidence, management, and long-term outcome of the two previously described subgroups of patients. METHODS: Systematic review and meta-analysis of surgical series that defined remission according to the 2010 biochemical criteria. RESULTS: We included 13 studies (1105 patients). The pooled rate of overall surgical remission was 54.8 % (95 % CI 44.4-65.2 %), and 72.2 % with previous criteria. Remission was achieved in 77.9 % (95 % CI 68.1-87.6 %) of microadenomas; 52.7 % (95 % CI 41-64.4 %) of macroadenomas; 29 % (95 % CI 20.1-37.8 %) of invasive and 68.8 % (95 % CI 60-77.6 %) of non-invasive adenomas. Complication rates were 1.2 % (95 % CI 0.6-1.9 %) for CSF leak, 1.3 % (95 % CI 0.6-2.1 %) for permanent diabetes insipidus, 8.7 % (95 % CI 4.8-12.5 %) for new anterior pituitary dysfunction and 0.6 % (95 % CI 0.1-1.1 %) for severe intraoperative hemorrhage. We identified an intermediate group of patients, defined as: (1) Remission according to one, but not the other biochemical criteria (GH or IGF-1) or 2010 criteria (14.3 % and 47.1 % cases), (2) Remission according to 2000, but not 2010 criteria (13.2-58.8 % cases). Two studies reported a remission rate of 56.5 % and 100 %, in the two subgroups respectively, in a long-term outcome without adjuvant therapy. CONCLUSIONS: Overall remission with transsphenoidal surgery is achieved in ∼55 % of patients. For the intermediate group of patients, future prospective studies with long-term follow-up are required to determine the long-term biochemical remission rates and clinical implications.
BACKGROUND: In 2010, the Acromegaly Consensus Group revised the criteria for cure of acromegaly and thus rates of surgical remission need to be revised in light of these new thresholds. Two subgroups consisted of patients with discordant GH and IGF-1 levels and patients in remission according to the 2000 criteria, but not to the 2010 criteria, have been reported after adenomectomy and for these subgroups the precise incidence and management has not been established. The objective of the study was to update rates of surgical remission and complications and to evaluate the incidence, management, and long-term outcome of the two previously described subgroups of patients. METHODS: Systematic review and meta-analysis of surgical series that defined remission according to the 2010 biochemical criteria. RESULTS: We included 13 studies (1105 patients). The pooled rate of overall surgical remission was 54.8 % (95 % CI 44.4-65.2 %), and 72.2 % with previous criteria. Remission was achieved in 77.9 % (95 % CI 68.1-87.6 %) of microadenomas; 52.7 % (95 % CI 41-64.4 %) of macroadenomas; 29 % (95 % CI 20.1-37.8 %) of invasive and 68.8 % (95 % CI 60-77.6 %) of non-invasive adenomas. Complication rates were 1.2 % (95 % CI 0.6-1.9 %) for CSF leak, 1.3 % (95 % CI 0.6-2.1 %) for permanent diabetes insipidus, 8.7 % (95 % CI 4.8-12.5 %) for new anterior pituitary dysfunction and 0.6 % (95 % CI 0.1-1.1 %) for severe intraoperative hemorrhage. We identified an intermediate group of patients, defined as: (1) Remission according to one, but not the other biochemical criteria (GH or IGF-1) or 2010 criteria (14.3 % and 47.1 % cases), (2) Remission according to 2000, but not 2010 criteria (13.2-58.8 % cases). Two studies reported a remission rate of 56.5 % and 100 %, in the two subgroups respectively, in a long-term outcome without adjuvant therapy. CONCLUSIONS: Overall remission with transsphenoidal surgery is achieved in ∼55 % of patients. For the intermediate group of patients, future prospective studies with long-term follow-up are required to determine the long-term biochemical remission rates and clinical implications.
Entities:
Keywords:
Acromegaly; Growth hormone-secreting pituitary adenoma; Remission; Transsphenoidal surgery
Authors: S Zhang; J Chen; Y Zhu; H Wang; Z Mao; S Yao; F Akter; Z Wang; B Hu; D Zhu; C Duan; W Chen Journal: J Endocrinol Invest Date: 2022-09-20 Impact factor: 5.467
Authors: Eva C Coopmans; Mark R Postma; Thalijn L C Wolters; Sebastiaan W F van Meyel; Romana Netea-Maier; André P van Beek; Sebastian J C M M Neggers Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Laura Van Gerven; Zhen Qian; Anastasiya Starovoyt; Mark Jorissen; Jeroen Meulemans; Johannes van Loon; Steven De Vleeschouwer; Julie Lambert; Marie Bex; Vincent Vander Poorten Journal: Front Oncol Date: 2021-05-07 Impact factor: 6.244
Authors: Ahmed Mohyeldin; Laurence J Katznelson; Andrew R Hoffman; Karam Asmaro; Saman S Ahmadian; Mostafa M Eltobgy; Jayakar V Nayak; Zara M Patel; Peter H Hwang; Juan C Fernandez-Miranda Journal: Sci Rep Date: 2022-06-15 Impact factor: 4.996
Authors: David P Bray; Sai Mannam; Rima S Rindler; Joseph W Quillin; Nelson M Oyesiku Journal: Front Endocrinol (Lausanne) Date: 2022-08-04 Impact factor: 6.055
Authors: Giulia Cossu; Emmanuel Jouanneau; Luigi M Cavallo; Sebastien Froelich; Daniele Starnoni; Lorenzo Giammattei; Ethan Harel; Diego Mazzatenta; Micheal Bruneau; Torstein R Meling; Moncef Berhouma; Ari G Chacko; Jan F Cornelius; Dimitrios Paraskevopoulos; Henry W S Schroeder; Idoya Zazpe; Romain Manet; Paul A Gardner; Henry Dufour; Paolo Cappabianca; Roy T Daniel; Mahmoud Messerer Journal: Brain Spine Date: 2022-03-28